Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioInvent International AB ( (SE:BINV) ) just unveiled an update.
BioInvent International AB has announced strategic changes to focus on its most advanced clinical assets, aiming to maximize patient impact and shareholder value. The company has several upcoming milestones, including data releases for its BI-1808 and BI-1206 programs, which could significantly impact its positioning in the immuno-oncology field.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK41.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a biotechnology company focused on the development of immuno-oncology therapies. The company specializes in creating antibodies that target cancer cells, with a market focus on advancing treatments for various types of cancer, including solid tumors and lymphomas.
Average Trading Volume: 77,979
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.38B
See more data about BINV stock on TipRanks’ Stock Analysis page.